Comparative Pharmacology
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus SILENOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOMIPRAMINE HYDROCHLORIDE versus SILENOR.
CLOMIPRAMINE HYDROCHLORIDE vs SILENOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Selective histamine H1 receptor antagonist; promotes sleep by antagonizing central histaminergic neurotransmission.
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
6 mg orally once daily at bedtime, not to exceed 6 mg/day.
None Documented
None Documented
Terminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
Terminal elimination half-life is approximately 10 hours (range 8-15 hours) in healthy adults; prolonged in elderly and hepatic impairment.
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Primarily renal (approximately 60% as unchanged drug and metabolites), with 30% fecal elimination.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant